Drugs / NMRA-323511
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06546995 | Jul 2024 → Nov 2025 | Alzheimer disease | Neumora Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NMRA-323511 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06546995 ↗ |
| Route | Oral | “Participants will receive NMRA-323511 orally.” NCT06546995 ↗ |